Nektar Therapeutics (AL)
490 Discovery Drive
Huntsville
Alabama
35806
U.S.A.
Phone:
256-533-4201
Fax:
256-533-4805
|
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its proprietary polymer conjugation technology platform. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas.
In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in preclinical studies, including a new opioid compound scheduled to enter clinical development in 2011.
In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.
Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Email:
nektarAL@nektar.com
Ownership:
Public
Web Site:
Nektar Therapeutics (AL)
Employees:
Symbol: NKTR
|